BRAIDWELL LP
CIK 1920938 · EDGAR ↗
- sum of disclosed values for 2026-03-31; 0 positions have no disclosed value and are left out of the sum, counted here rather than dropped
- $3.0B
- every reported holding for this filer and quarter, including ones with no disclosed value
- 88
- positions with no comparable holding in the prior quarter (kind new), 2026-03-31
- 31
- positions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
- 16
Quarter-end snapshot, filed up to 45 days later — not current holdings. What a 13F covers ↓
Changes · Quarter ended 2026-03-31. Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
by shares · How classified ↗Period
| The reviewed ticker for the filed issuer name and share class, the same mapping the Reported positions table uses. Symbols are never inferred from names; — means no reviewed mapping. | position matched across quarters by exact reported CUSIP over a registry gap — never a name match | NEW / ADD / TRIM / EXIT by share count · NO CHANGE = same shares; the value moved with price, so never an ADD or a TRIM · EXIT = absent this quarter (disposed, delisted, confidential, or reported by an affiliate) — the filing does not say which · NO PRIOR = no comparable prior quarter on record (a first filing, or a quarter filed inside an affiliate's report), so not called a new stake · n/c = not classifiable: value undisclosed on one side of the pair, or neither shares nor value can classify it · †v: the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE | derived by Public Filings from the published data; “no value” means the source did not disclose a usable value — never zero | Prev value | Curr value | Prev shares | Curr shares | |
|---|---|---|---|---|---|---|---|---|
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:14212 · issuer key iss:396 | ADD | −$67.7M | +193,305 | $211M | $143M | 7,816,142 | 8,009,447 |
| — | share class as filed: DEBT 1.250% 2/1 · position key pos:17241 · issuer key iss:860 PRN | TRIM | −$89.7M | −43,900,000 | $192M | $103M | 104,854,000 | 60,954,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:11462 · issuer key iss:1296 | TRIM | −$20.7M | −99,413 | $107M | $85.9M | 751,534 | 652,121 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:15808 · issuer key iss:825 | TRIM | −$21.9M | −158,474 | $104M | $82.2M | 921,979 | 763,505 |
| — | share class as filed: SPONSORED ADS · position key pos:17964 · issuer key iss:2365 | TRIM | +$24.2M | −201,552 | $54.7M | $78.9M | 2,188,320 | 1,986,768 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:12517 · issuer key iss:1997 | TRIM | −$4.0M | −486,624 | $81.8M | $77.8M | 1,825,076 | 1,338,452 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:17547 · issuer key iss:577 | TRIM | +$23.0M | −374,571 | $52.5M | $75.5M | 1,273,935 | 899,364 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:11808 · issuer key iss:635 | TRIM | −$55.4M | −2,863,248 | $129M | $73.9M | 5,210,831 | 2,347,583 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:12344 · issuer key iss:946 | ADD | +$33.4M | +392,847 | $38.6M | $72.0M | 217,345 | 610,192 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:13206 · issuer key iss:1335 | TRIM | −$10.9M | −120,977 | $82.6M | $71.8M | 821,406 | 700,429 |
| — | share class as filed: COM · position key sid:sec:prov:b6301632224d8122ae8dff0115962cfa · issuer key cusip6:50015M | TRIM | +$11.4M | −254,123 | $58.0M | $69.3M | 2,072,788 | 1,818,665 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:11549 · issuer key iss:429 | TRIM | −$11.0M | −885,788 | $77.7M | $66.7M | 1,870,571 | 984,783 |
| — | share class as filed: NOTE 0.750% 3/1 · position key sid:sec:prov:8a6c9e7c10d352cf3600836fd828df64 · issuer key iss:2334 PRN | NEW | +$63.4M | +61,621,000 | $0 | $63.4M | — | 61,621,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: SPONSORED ADR · position key pos:17260 · issuer key iss:165 | ADD | +$36.0M | +53,932 | $26.1M | $62.0M | 31,007 | 84,939 |
| — | share class as filed: CL A · position key sid:sec:prov:15b122a1959cdc720dffb69686bc9994 · issuer key cusip6:433313 | ADD | −$4.5M | +150,500 | $60.6M | $56.1M | 1,304,623 | 1,455,123 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:17971 · issuer key iss:30 | ADD | +$734K | +439,178 | $54.3M | $55.0M | 2,032,021 | 2,471,199 |
| — | share class as filed: COM · position key sid:sec:prov:3224bd4d4c1e7dd823e99e6304f866c2 · issuer key cusip6:61225M | ADD | +$37.9M | +2,258,258 | $14.9M | $52.7M | 948,316 | 3,206,574 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:16881 · issuer key iss:1079 | TRIM | −$2.7M | −19,676 | $49.8M | $47.1M | 202,101 | 182,425 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM NEW · position key pos:13625 · issuer key iss:45 | TRIM | −$6.5M | −701,792 | $53.5M | $47.1M | 1,634,615 | 932,823 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:17626 · issuer key iss:860 | NEW | +$46.2M | +499,712 | $0 | $46.2M | — | 499,712 |
Flags: no row carries a flag.
1–20 of the 98 changes on this page
Mark-to-market only (no share change) · 6
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
| The reviewed ticker for the filed issuer name and share class, the same mapping the Reported positions table uses. Symbols are never inferred from names; — means no reviewed mapping. | position matched across quarters by exact reported CUSIP over a registry gap — never a name match | NEW / ADD / TRIM / EXIT by share count · NO CHANGE = same shares; the value moved with price, so never an ADD or a TRIM · EXIT = absent this quarter (disposed, delisted, confidential, or reported by an affiliate) — the filing does not say which · NO PRIOR = no comparable prior quarter on record (a first filing, or a quarter filed inside an affiliate's report), so not called a new stake · n/c = not classifiable: value undisclosed on one side of the pair, or neither shares nor value can classify it · †v: the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE | derived by Public Filings from the published data; “no value” means the source did not disclose a usable value — never zero | Prev value | Curr value | Prev shares | Curr shares | |
|---|---|---|---|---|---|---|---|---|
| — | share class as filed: NOTE 1.000%12/1 · position key pos:12320 · issuer key iss:1545 PRN | NO CHANGE | −$12.2M | 0 | $111M | $98.7M | 101,000,000 | 101,000,000 |
| — | share class as filed: NOTE 0.250% 1/1 · position key pos:13892 · issuer key iss:1286 PRN | NO CHANGE | +$2.1M | 0 | $89.7M | $91.8M | 100,381,000 | 100,381,000 |
| — | share class as filed: COM · position key sid:sec:prov:71e6d7a9978be392e4db6948ea1b496a · issuer key cusip6:68752L | NO CHANGE | −$2.1M | 0 | $19.5M | $17.5M | 1,100,370 | 1,100,370 |
| — | share class as filed: COM · position key sid:sec:prov:3c1bdde45f78766466db92da273259f5 · issuer key cusip6:30052C | NO CHANGE | −$7.9M | 0 | $20.6M | $12.8M | 3,105,209 | 3,105,209 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:12631 · issuer key iss:843 | NO CHANGE | −$4.8M | 0 | $12.2M | $7.4M | 142,755 | 142,755 |
| — | share class as filed: COM · position key sid:sec:prov:d2d26810594465634746ea83805ad7e9 · issuer key cusip6:745848 | NO CHANGE | −$692K | 0 | $1.7M | $971K | 752,541 | 752,541 |
Flags: no row carries a flag.
Holdings without a security ID are counted, not compared. Method ↗
Reported positions — 2026-03-31
84 issuers · 88 rowsViewThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
| This list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | a position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | Share of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | value undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Wt | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GUARDANT HEALTH INC | $149M | — | 5.0% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CARIS LIFE SCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $143M | 8,009,447 | 4.8% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEOGENOMICS INC | $134M | — | 4.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REPLIGEN CORP | $104M | — | 3.5% | |||||||
| — | ALPHATEC HLDGS INC2 positions · 2 reported rows
| $87.0M | — | 2.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEUROCRINE BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.9M | 652,121 | 2.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GLAUKOS CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $82.2M | 763,505 | 2.7% | |||||||
| — | CENTESSA PHARMACEUTICALS PLC · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $78.9M | 1,986,768 | 2.6% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $77.8M | 1,338,452 | 2.6% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DIANTHUS THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $75.5M | 899,364 | 2.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $73.9M | 2,347,583 | 2.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IRHYTHM HOLDINGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $72.0M | 610,192 | 2.4% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NUVALENT INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $71.8M | 700,429 | 2.4% | |||||||
| — | KODIAK SCIENCES INC · COM CUSIP 50015M109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $69.3M | 1,818,665 | 2.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CG ONCOLOGY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $66.7M | 984,783 | 2.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARGENX SE · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $62.0M | 84,939 | 2.1% | |||||||
| — | HINGE HEALTH INC · CL A CUSIP 433313103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $56.1M | 1,455,123 | 1.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $55.0M | 2,471,199 | 1.8% | |||||||
| — | MONTE ROSA THERAPEUTICS INC · COM CUSIP 61225M102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $52.7M | 3,206,574 | 1.8% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KRYSTAL BIOTECH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $47.1M | 182,425 | 1.6% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SPYRE THERAPEUTICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $47.1M | 932,823 | 1.6% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | THERMO FISHER SCIENTIFIC INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $45.7M | 92,915 | 1.5% | |||||||
| — | GENERATE BIOMEDICINES INC · COM SHS CUSIP 370920100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $44.9M | 3,592,999 | 1.5% | |||||||
| — | MBX BIOSCIENCES INC · COM CUSIP 55287L101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $44.6M | 1,492,467 | 1.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIGHTSPRING HEALTH SVCS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $43.3M | 1,016,562 | 1.4% | |||||||
| — | CELLDEX THERAPEUTICS INC NEW · COM NEW CUSIP 15117B202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $43.0M | 1,356,082 | 1.4% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | APOGEE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $40.3M | 478,667 | 1.3% | |||||||
| — | BRIGHT MINDS BIOSCIENCES INC · COM NEW CUSIP 10919W405 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $39.4M | 539,708 | 1.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CAREDX INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.7M | 2,173,146 | 1.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INTUITIVE SURGICAL INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.6M | 77,297 | 1.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSPIRE MED SYS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.9M | 677,570 | 1.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PENUMBRA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.6M | 105,352 | 1.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TRANSMEDICS GROUP INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $32.7M | 329,391 | 1.1% | |||||||
| — | SOLENO THERAPEUTICS INC · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $32.1M | 959,259 | 1.1% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DYNE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.5M | 1,681,998 | 1.0% | |||||||
| — | MARAVAI LIFESCIENCES HLDGS I · COM CL A CUSIP 56600D107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $29.0M | 10,240,164 | 1.0% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ILLUMINA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $28.3M | 229,215 | 0.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KYMERA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $28.1M | 337,559 | 0.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOMARIN PHARMACEUTICAL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $28.1M | 497,020 | 0.9% | |||||||
| — | NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $27.1M | 1,750,766 | 0.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | RHYTHM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.0M | 310,628 | 0.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DANAHER CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.4M | 139,327 | 0.9% | |||||||
| — | ESTABLISHMENT LABS HLDGS INC · COM CUSIP G31249108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $26.3M | 463,600 | 0.9% | |||||||
| — | TECTONIC THERAPEUTIC INC · COM CUSIP 878972108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $26.2M | 847,151 | 0.9% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NATERA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.8M | 129,000 | 0.9% | |||||||
| — | CORVUS PHARMACEUTICALS INC · COM CUSIP 221015100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $25.6M | 1,752,798 | 0.9% | |||||||
| — | FULCRUM THERAPEUTICS INC · COM CUSIP 359616109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $24.0M | 3,134,922 | 0.8% | |||||||
| — | ZURA BIO LTD · CLASS A ORD SHS CUSIP G9TY5A101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $23.7M | 3,988,989 | 0.8% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DAMORA THERAPEUTICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $23.2M | 894,846 | 0.8% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BOSTON SCIENTIFIC CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.7M | 346,467 | 0.7% | |||||||
| — | VERA THERAPEUTICS INC · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $21.1M | 523,824 | 0.7% | |||||||
| — | BIOAGE LABS INC · COM CUSIP 09077V100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $21.0M | 1,200,587 | 0.7% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CVS HEALTH CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.9M | 290,700 | 0.7% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.6M | 265,715 | 0.6% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELEVANCE HEALTH INC FORMERLY · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.2M | 62,080 | 0.6% | |||||||
| — | ORTHOPEDIATRICS CORP · COM CUSIP 68752L100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $17.5M | 1,100,370 | 0.6% | |||||||
| — | ENGENE HOLDINGS INC · COM CUSIP 29286M105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $16.7M | 2,456,870 | 0.6% | |||||||
| — | NEKTAR THERAPEUTICS · COM NEW CUSIP 640268306 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $16.0M | 222,701 | 0.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA HEALTHCARE COMPANY IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $15.1M | 645,900 | 0.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORIC PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.3M | 1,128,040 | 0.5% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AVEANNA HEALTHCARE HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.2M | 2,203,506 | 0.5% | |||||||
| — | X4 PHARMACEUTICALS INC · COM NEW CUSIP 98420X202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $13.5M | 3,272,954 | 0.5% | |||||||
| — | ZENAS BIOPHARMA INC · NOTE 2.500% 4/0 CUSIP 98937LAA3 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $13.5M | 13,000,000 PRN | 0.4% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KINIKSA PHARMACEUTICALS INTL · ORD SHS CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.1M | 272,522 | 0.4% | |||||||
| — | EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $12.8M | 3,105,209 | 0.4% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TG THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.9M | 358,800 | 0.4% | |||||||
| — | SURROZEN INC · COM NEW CUSIP 86889P208 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $11.5M | 396,100 | 0.4% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CENTENE CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.8M | 330,000 | 0.4% | |||||||
| — | CLIMB BIO INC · COM CUSIP 28658R106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $10.5M | 1,529,675 | 0.3% | |||||||
| — | COMPASS THERAPEUTICS INC · COM CUSIP 20454B104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $10.4M | 1,965,106 | 0.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.8M | 130,862 | 0.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | HELIX ACQUISITION CORP III · USD CL A ORD SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.3M | 900,000 | 0.3% | |||||||
| — | VOR BIOPHARMA INC · COM NEW CUSIP 929033207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $8.3M | 466,774 | 0.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.3M | 84,900 | 0.3% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GRAIL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.4M | 142,755 | 0.2% | |||||||
| — | ACLARIS THERAPEUTICS INC · COM CUSIP 00461U105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $6.4M | 1,699,116 | 0.2% | |||||||
| — | DENALI THERAPEUTICS INC · COM CUSIP 24823R105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $5.7M | 296,324 | 0.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | HARROW INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.5M | 156,419 | 0.2% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVVITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.2M | 48,400 | 0.1% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.3M | 29,198 | 0.1% | |||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.2M | 9,976 | 0.1% | |||||||
| — | ARROWHEAD PHARMACEUTICALS IN · NOTE 1/1 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $2.3M | 2,250,000 PRN | 0.1% | |||||||
| — | PULMONX CORP · COM CUSIP 745848101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $971K | 752,541 | 0.0% | |||||||
| — | VYNE THERAPEUTICS INC · COM CUSIP 92941V308 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $547K | 916,077 | 0.0% |
1–20 of 84 issuers
1–84 of 84 issuers · page 1 of 1
One line per issuer, largest first — open a line for its reported rows. Grouping ↗
Book shape
Tick = median of the 8,748 tracked filers with a 2026-03-31 book (the index median: the 8,662 with a complete book). Concentration uses reported 13F long value, not total assets; the index is withheld when any position lacks a value.- 58.5%below median 80.0%
- integer Herfindahl–Hirschman index in basis points over disclosed position values
- 187 bpsbelow median 446 bps
- holdings with no disclosed value (undisclosed, or unreadable on the filing) — kept and counted, never shown as zero
- 88 / 88median book 97.5 positions
104 quarter-over-quarter rows
Filing history
| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
Complete source filings on SEC EDGAR
The filing on EDGAR is the record, including any filed after this build.
Open BRAIDWELL LP's 13F filings on SEC EDGAR ↗A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings: a position may have changed or closed since the quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars; each record notes its original unit.
Affiliated managers may report the same position, so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice.